Oral terbinafine (Lamisil®) in the short-term treatment of fungal infections of the skin: results of a post-marketing surveillance study

Oral terbinafine (Lamisil®, Novartis Pharma AG, Basel, Switzerland) is an effective therapy for fungal infections of the skin and nails. A post‐marketing surveillance study was undertaken to evaluate the clinical efficacy and safety of oral terbinafine. A total of 454 patients with clinically and my...

Full description

Saved in:
Bibliographic Details
Published inMycoses Vol. 42; no. 9-10; pp. 555 - 558
Main Authors Binder, M., Nell, G.
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.11.1999
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Oral terbinafine (Lamisil®, Novartis Pharma AG, Basel, Switzerland) is an effective therapy for fungal infections of the skin and nails. A post‐marketing surveillance study was undertaken to evaluate the clinical efficacy and safety of oral terbinafine. A total of 454 patients with clinically and mycologically confirmed superficial fungal infections of the skin were enrolled from 79 dermatology clinics. Patients received oral terbinafine (250 mg day−1) for 2 weeks. Specific signs and symptoms were assessed by standard questionnaire before, immediately after, and 4 weeks after treatment. Observed improvements in patients after 2 weeks treatment were: erythema 81%, blistering 33%, exudation 50%, scaling 89%, pruritus 83%. After 4 weeks treatment, erythema was absent in 85% of patients, blistering and exudation in 99.7%, scaling in 82%, and pruritus in 94%. Overall clinical efficacy was assessed as good to excellent in 97% of patients. Adverse effects – mainly gastrointestinal and minor skin rashes – were reported in 5.3% of patients. The results of this study confirm that oral terbinafine is safe and highly effective for the short‐term treatment of fungal skin infections.
Bibliography:ArticleID:MYC515
istex:1D3DF264291AEC566C05CBE814F9006EF095C159
ark:/67375/WNG-4H3S04G8-K
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ISSN:0933-7407
1439-0507
DOI:10.1046/j.1439-0507.1999.00515.x